Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2a Open-Label Study to Investigate the Safety of the Transplantation (by Injection) of Human Glial Restricted Progenitor Cells (hGRPs; Q-Cells) Into Subjects With Transverse Myelitis (TM)

Trial Profile

A Phase 1/2a Open-Label Study to Investigate the Safety of the Transplantation (by Injection) of Human Glial Restricted Progenitor Cells (hGRPs; Q-Cells) Into Subjects With Transverse Myelitis (TM)

Status: Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 13 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Glial stem cell therapy (Primary)
  • Indications Transverse myelitis
  • Focus Adverse reactions; First in man
  • Sponsors Q Therapeutics
  • Most Recent Events

    • 10 Sep 2019 Planned initiation date changed from 1 Jun 2019 to 20 Dec 2019.
    • 20 Mar 2019 Status changed from planning to not yet recruiting.
    • 27 Jul 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top